211 related articles for article (PubMed ID: 33969605)
1. Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion.
Jobe NP; Åsberg L; Andersson T
Mol Oncol; 2021 Jul; 15(7):1835-1848. PubMed ID: 33969605
[TBL] [Abstract][Full Text] [Related]
2. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.
Klein RM; Higgins PJ
Mol Cancer; 2011 Sep; 10():114. PubMed ID: 21917148
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion.
Linnskog R; Mohapatra P; Moradi F; Prasad CP; Andersson T
Oncotarget; 2016 Jun; 7(25):37790-37802. PubMed ID: 27191257
[TBL] [Abstract][Full Text] [Related]
4. Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration.
Moradi F; Berglund P; Linnskog R; Leandersson K; Andersson T; Prasad CP
Transl Res; 2016 Jun; 172():45-60. PubMed ID: 26970271
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
6. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion.
Jenei V; Sherwood V; Howlin J; Linnskog R; Säfholm A; Axelsson L; Andersson T
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19473-8. PubMed ID: 19901340
[TBL] [Abstract][Full Text] [Related]
7. Daam1 activates RhoA to regulate Wnt5a‑induced glioblastoma cell invasion.
Liu G; Yan T; Li X; Sun J; Zhang B; Wang H; Zhu Y
Oncol Rep; 2018 Feb; 39(2):465-472. PubMed ID: 29207169
[TBL] [Abstract][Full Text] [Related]
8. WNT5A: a motility-promoting factor in Hodgkin lymphoma.
Linke F; Zaunig S; Nietert MM; von Bonin F; Lutz S; Dullin C; Janovská P; Beissbarth T; Alves F; Klapper W; Bryja V; Pukrop T; Trümper L; Wilting J; Kube D
Oncogene; 2017 Jan; 36(1):13-23. PubMed ID: 27270428
[TBL] [Abstract][Full Text] [Related]
9. Diverse matrix metalloproteinase functions regulate cancer amoeboid migration.
Orgaz JL; Pandya P; Dalmeida R; Karagiannis P; Sanchez-Laorden B; Viros A; Albrengues J; Nestle FO; Ridley AJ; Gaggioli C; Marais R; Karagiannis SN; Sanz-Moreno V
Nat Commun; 2014 Jun; 5():4255. PubMed ID: 24963846
[TBL] [Abstract][Full Text] [Related]
10. Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis.
Deng X; Tu Z; Xiong M; Tembo K; Zhou L; Liu P; Pan S; Xiong J; Yang X; Leng J; Zhang Q; Xiao R; Zhang Q
Oncotarget; 2017 Jun; 8(24):39033-39047. PubMed ID: 28380463
[TBL] [Abstract][Full Text] [Related]
11. Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion.
Ekström EJ; Sherwood V; Andersson T
PLoS One; 2011 Apr; 6(4):e18674. PubMed ID: 21494614
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression.
Linnskog R; Jönsson G; Axelsson L; Prasad CP; Andersson T
Mol Oncol; 2014 Dec; 8(8):1365-78. PubMed ID: 24954857
[TBL] [Abstract][Full Text] [Related]
13. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.
Ekström EJ; Bergenfelz C; von Bülow V; Serifler F; Carlemalm E; Jönsson G; Andersson T; Leandersson K
Mol Cancer; 2014 Apr; 13():88. PubMed ID: 24766647
[TBL] [Abstract][Full Text] [Related]
14. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
15. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition.
Prasad CP; Chaurasiya SK; Guilmain W; Andersson T
J Exp Clin Cancer Res; 2016 Sep; 35(1):144. PubMed ID: 27623766
[TBL] [Abstract][Full Text] [Related]
16. Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling.
Yadav V; Jobe N; Satapathy SR; Mohapatra P; Andersson T
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551563
[TBL] [Abstract][Full Text] [Related]
17. PKCα promotes the mesenchymal to amoeboid transition and increases cancer cell invasiveness.
Vaškovičová K; Szabadosová E; Čermák V; Gandalovičová A; Kasalová L; Rösel D; Brábek J
BMC Cancer; 2015 Apr; 15():326. PubMed ID: 25924946
[TBL] [Abstract][Full Text] [Related]
18. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
[TBL] [Abstract][Full Text] [Related]
19. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.
Webster MR; Xu M; Kinzler KA; Kaur A; Appleton J; O'Connell MP; Marchbank K; Valiga A; Dang VM; Perego M; Zhang G; Slipicevic A; Keeney F; Lehrmann E; Wood W; Becker KG; Kossenkov AV; Frederick DT; Flaherty KT; Xu X; Herlyn M; Murphy ME; Weeraratna AT
Pigment Cell Melanoma Res; 2015 Mar; 28(2):184-95. PubMed ID: 25407936
[TBL] [Abstract][Full Text] [Related]
20. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.
Radaszkiewicz T; Nosková M; Gömöryová K; Vondálová Blanářová O; Radaszkiewicz KA; Picková M; Víchová R; Gybeľ T; Kaiser K; Demková L; Kučerová L; Bárta T; Potěšil D; Zdráhal Z; Souček K; Bryja V
Elife; 2021 Oct; 10():. PubMed ID: 34702444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
